赛诺菲与葛兰素史克新冠疫苗加强针初步数据良好
赛诺菲(SNY.US)与葛兰素史克(GSK.US)新冠疫苗加强针初步数据良好
智通财经APP获悉，赛诺菲(NASDAQ:SNY)(PA:AVEPp)与葛兰素史克(NYSE:GSK)(LON:GSK)宣布新冠疫苗加强针初步数据良好。据悉，VAT0002临床试验的初步结果表明，无论接受的主要疫苗是什么，对于所有受试年龄组来说，注射单次加强剂量都会使其中和抗体增加9到43倍。在研究中，加强针的耐受性良好，预计在2022年上半年将有更多的试验数据。
这两家公司还指出，独立数据安全监测委员会在最近一次审查其正在进行的全球第三阶段试验VAT0008时未发现任何安全问题，并建议该试验持续到2022年初，以积累更多数据，第三期试验结果预计在明年第一季度公布。
More Stories
Oil inches higher as Middle East tensions heat up
© Reuters. Army soldier miniatures and stock graph are seen in this illustration taken October 9, 2023. REUTERS/Dado Ruvic/Illustration/File Photo...
Asian stocks rise before US CPI; Japan’s Nikkei extends rally
. JP225 +1.88% Add to/Remove from Watchlist Add to Watchlist Add Position Position added successfully to: + Add another position...
SEC approves spot Bitcoin ETFs
. SEC approves spot bitcoin ETFs BTC/USD +1.76% Add to/Remove from Watchlist Add to Watchlist Add Position Position added successfully...
Google lays off hundreds in Assistant, hardware, engineering teams
© Reuters. The Google logo is seen on the Google house at CES 2024, an annual consumer electronics trade show,...
Amazon has not offered remedies to EU concerns over iRobot deal
© Reuters. FILE PHOTO: The logo of Amazon is seen at the company's logistics centre in Boves, France, October 6,...
Stocks climb as megacaps lead; inflation data, earnings on deck
© Reuters. FILE PHOTO: People walk around the Financial District near the New York Stock Exchange (NYSE) in New York,...